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The computational study of human metabolism has been advanced with the advent of the ﬁrst
generic (non-tissue speciﬁc) stoichiometric model of human metabolism. In this study, we present
a new algorithm for rapid reconstruction of tissue-speciﬁc genome-scale models of human
metabolism. The algorithm generates a tissue-speciﬁc model from the generic human model by
integrating a variety of tissue-speciﬁc molecular data sources, including literature-based knowl-
edge, transcriptomic, proteomic, metabolomic and phenotypic data. Applying the algorithm, we
constructed the ﬁrst genome-scale stoichiometric model of hepatic metabolism. The model is
veriﬁed using standard cross-validation procedures, and through its ability to carry out hepatic
metabolicfunctions.Themodel’sﬂuxpredictionscorrelatewithﬂuxmeasurementsacrossavariety
of hormonal and dietary conditions, and improve upon the predictive performance obtained using
the original, generic human model (prediction accuracy of 0.67 versus 0.46). Finally, the model
better predicts biomarker changes in genetic metabolic disorders than the generic human
model (accuracy of 0.67 versus 0.59). The approach presented can be used to construct other
human tissue-speciﬁc models, and be applied to other organisms.
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Introduction
The understanding of human metabolism is crucial for the
study and treatment of a diverse and wide range of clinical
conditions, ranging from common metabolic disorders, such
as obesity and diabetes, to rare inborn errors of metabolism
(IEMs). Carcinogenesis is also known to involve abnormal
metabolic phenotypes, and metabolic targets have long been
used in cancer chemotherapy (Serkova et al, 2007; Galmarini
etal,2008).Recently,malfunctionsinenergymetabolismwere
shown to be involved in various brain disorders, from
schizophrenia to neurodegenerative disorders (Holmes et al,
2006; Huang et al, 2007). The computational study of human
metabolism could complement experimental investigations of
these central medical problems providing insights into their
pathophysiology and advancing their treatment.
Mathematical modeling of cellular metabolism has tradi-
tionally been performed through kinetic modeling techniques
that require detailed information on kinetic constants and
on enzyme and metabolite levels (Garﬁnkel and Hess,
1964). However, the lack of accurate cellular information of
enzymes’ kinetics and levels currently limits the applicability
of such methods to small-scale systems. An alternative
computational approach, constraint-based modeling (CBM),
bypasses these hurdles as it does not depend on such detailed
information. Constraint-based modeling assumes a metabolic
steady state under which feasible ﬂux distributions satisfy a
stoichiometric mass-balance requirement, thermodynamic
constraints and constraints on enzymes’ capacities that are
based on experimental observations of ﬂux rates. This
modeling paradigm has been extensively applied with
considerable success to study microbial physiology (Edwards
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and Palsson, 2008; AbuOun et al, 2009; Durot et al, 2009;
KumarandMaranas,2009;Oberhardt etal,2009).Though still
less developed, large-scale modeling of human metabolism
is constantly progressing (Goodacre et al, 2004); earlier
study has focused on characterizing distinct human metabolic
pathways (Kanehisa and Goto, 2000; Romero et al, 2004),
and modeling speciﬁc cell types and organelles (Wiback
and Palsson, 2002; Chatziioannou et al, 2003; Vo et al,
2004).
In 2007, two generic human metabolic models were
presented on the basis of an extensive evaluation of genomic
and bibliomic data (Duarte et al, 2007; Ma et al, 2007). These
network models consist of a collection of biochemical
reactions that may take place under different tissues and cell
types, depending on physiological conditions. The potential
clinical utility of the generic model was previously demon-
strated by its ability to identify functionally related sets of
reactions that are causally related to hemolytic anemia, and
potential drug targets for treating hypercholesterolemia
(Duarte et al, 2007). In a recent study, the utility of this
generic human metabolic model was further demonstrated in
predicting metabolic biomarkers whose concentration is
altered due to genomic mutations in IEMs (Shlomi et al,
2009). Addressing the challenge of using a generic human
model to predict tissue-speciﬁc metabolism, a computational
method for integrating a generic model with tissue-speciﬁc
gene and protein expression data was recently presented
(Shlomi et al, 2008). This study successfully predicted a
variety of metabolic behaviors of different human tissues,
including the brain, liver, kidney and more. The predicted
metabolic behavior characterizes, for each tissue, a single,
normal physiological condition under which the expression
data (used as input) was measured.
In this study, we develop a new computational method that
uses a variety of different tissue-speciﬁc molecular data
sources to reconstruct functional metabolic network models
of human tissues, rather than predicting a single metabolic
state of a tissue as shown in the study by Shlomi et al (2008).
Such models can then be used to explorethe metabolic state of
a tissue under various genetic and physiological conditions
through standard CBM methods, without requiring additional
context-speciﬁc molecular data. More speciﬁcally, although in
the previous approach of Shlomi et al (2008) one could not
simulate and study the effects of genetic perturbations or drug
applications, this can now be performed in a straightforward
manner given the model constructed in this study. Notably,
harnessing the mixed-integer linear programming approach
used in the study by Shlomi et al (2008) to our current goal of
constructing a full-ﬂedged tissue model does not work—this is
due to the high computational demands put forward by
the many tissue-speciﬁc data sources required in this
study. Hence, alternatively, our new method is based on
heuristically pruning the generic human metabolic model to
derive a sub-network that is as consistent as possible with the
pertaining tissue-speciﬁc molecular data sources, including
literature-based knowledge, transcriptomic, proteomic, meta-
bolomic, and phenotypic data. Applying the new method to
generate the ﬁrst genome-scale metabolic model of the liver,
the resulting model is shown to be consistent with a variety of
hepaticdatasources,andtosuccessfullypermitthesimulation
of various metabolic states under different physiological
conditions, in a manner superior to that obtained using the
generic model.
Results
The model-building algorithm (MBA)
Ouralgorithmderivesatissue-speciﬁc metabolicmodel froma
generic model based on network integration with various
molecular data sources. We begin by ﬁrst inferring from the
tissue-speciﬁc data a set of reactions denoted as the core
reactions, that is, reactions that are included in the generic
model and should be included in the tissue model we aim to
build (see Materials and methods section). We differentiate
between core reactions that have a high versus moderate
probability to be carried out in the speciﬁc tissue and divide
the core into two sets, CH and CM, for high and moderate
likelihood reactions, respectively. In general, the CH set
includes human-curated tissue-speciﬁc pathways and the CM
set includes reactions testiﬁed by molecular data. Both the CH
and the CM are subsets of the generic model. The input to our
algorithm is a generic model that is composed of a union of
reactions that may exist in different, individual tissues (i.e., in
our case, the generic human model), and the core, tissue-
speciﬁcreactions(Figure1).Ourgoalisthentoderivethemost
parsimonious tissue-speciﬁc consistent model, which includes
all the tissue-speciﬁc high-probability reactions (CH), a
maximal number of moderate probability reactions (CM),
and a set of additional reactions from the generic model that is
required for gap ﬁlling—that is, for enabling the activation of
all core reactions, resulting in a fully viable and consistent
tissue-speciﬁc model. The latter reactions are observed by
Figure 1 The diagram illustrates the function of the model-building algorithm
(MBA). The algorithm is given tissue-speciﬁc core reactions sets (CH and CM)a s
input and reconstructs a tissue model containing all of the CH reactions, as many
aspossible CM reactions, and aminimal set of other generic model reactions that
are required for obtaining overall model consistency.
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obtain a consistent model—that is, a model in which for each
reaction there is an overall feasible ﬂux distribution inwhich it
is active. Aiming to ﬁnd the most parsimonious model on one
hand, and maximizing the number of moderate probability
reactions that are included in the model on the other hand,
inducesatradeoff. The latter istuned througha parameter that
weighs both optimization criteria to obtain a single score that
evaluates the quality of a model (see Materials and methods
section). Sensitivity analysis was preformed to examine the
reliance of the resulting model on this optimization parameter
(Supplementary information, pp 5–6), showing that MBA’s
performance is fairly robust and does not hinge upon a choice
of a narrow range of optimization parameter values.
To ﬁnd an optimal model with a maximal score, we use a
greedy heuristic search that is based on iteratively pruning
reactions from the generic model, in a random order, while
maintaining the consistency of the pruned model (starting
from a generic model that is consistent). In each pruning step,
a reaction is removed only if its removal does not prevent the
activation of reactions in CH, and its removal increases the
model’s score. As the reactions’ scanning order may affect the
resulting model, the algorithm is executed with different,
random pruning orders (1000 in our implementation) to
construct multiple candidate models (see Supplementary Figure
1 forfurtherclariﬁcation).The fraction of models that contains a
certain reaction reﬂects the conﬁdence that it should be included
in the ﬁnal tissue model. Hence, to construct the ﬁnal tissue
model, the candidate models are aggregated, starting from CH
and iteratively adding reactions ordered by their scores, until a
ﬁnal, minimal but consistent model is obtained.
Generating a metabolic model of the liver
We applied our method to automatically generate a genome-
scale metabolic network model of the liver. Our starting point
isthegenerichumanmetabolicmodelproposedbyDuarteetal
(2007), accounting for 2766 metabolites, 3742 reactions, 1905
genes, and 100 metabolic pathways. The essential core, CH,
was extracted from literature-based curation of tissue-speciﬁc
metabolic pathways that are known to be active in the liver
(Bocketal,1991;ChisariandFausto,2001;GropperandSmith,
2008; Rosenthal and Glew, 2009). It consists of 37 intact
metabolic pathways that are involved in central metabolism,
carbohydrate, lipid, and amino acids metabolism, as well as
speciﬁc hepatic metabolism (e.g., drug metabolism, bile acid
biosynthesis). These pathways involve in sum 779 reactions
and873metabolites.Themorepermissivecore,CM,consistsof
a set of 304 reactions, and 484 metabolites. It was assembled
from tissue-speciﬁc data sources, including metabolomic
(Wishart et al, 2007) transcriptomic (Shmueli et al, 2003;
Yanai et al, 2005), proteomic (Yan and Sadee, 2000; He, 2005;
Saieret al, 2006), andphenotypic data (McKusick, 2007) of the
liver (Supplementary information, data set I). Each reaction
was included in CM only if it was supported by at least two of
the data sources listed above, or if it was necessary for the
inclusion of a liver metabolite that appeared in the metabo-
lomics data (Wishart et al, 2007). The total core hence
comprises of 1083 reactions and 1187 metabolites (description
of reactions comprising the CH, CM, and ﬁnal liver model is
given in Supplementary information, data set I).
After applying our MBA method, the resulting liver model
consists of 1827 reactions and 1360 metabolites. The network
visualization is accessible through a supplemental website
(http://www.cs.technion.ac.il/~tomersh/methods.html)and
can be explored interactively using the freely available
Cytoscape software (Cline et al, 2007). Out of the reactions
in the derived liver model that are not included in either
reaction cores, 50% are transport reactions that transfer
metabolites across compartments (most of them are not
associated with genes in the model and hence could not be
included in the core reaction sets). The compartmentalization
pattern of the liver and the generic models is given in
Supplementary Figure 2. Notably, despite the heuristic nature
of the MBA algorithm, the participation of many of the
reactions in the resulting liver model is consistently predicted
across the different random reaction elimination orders. For
70.65% of the non-CH reactions the algorithm provides
completely unanimous predictions, that is, the reaction is
either present in all models or absent in all of them (Figure 2).
We ﬁrst tested the liver model by simulating various known
hepatic metabolic functions under different physiological
conditions. Evidently, even though the relevant metabolic
pathways were already used as input to the model reconstruc-
tion algorithm (within the set of high-reliability reactions, CH),
the resulting model is not guaranteed to have the capacity to
performcomplexfunctionsinvolvingtheintegrationofseveral
metabolic pathways. In the absence of available carbohy-
drates, hepatocytes have the unique ability to perform
gluconeogenesis, that is, to synthesize glucose through
glucogenic amino acids, glycerol, and lactate. We simulated
Figure 2 Coherency of the MBA model construction process, measured by the
distribution of non-CH (CM and non-core) reaction conﬁdence scores. As shown,
a high fraction of the reactions (70.65%) are predicted with complete certainty,
i.e., they appear either in all or in none of the sub-models generated.
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be used as carbon sources, apart from glucogenic amino acids,
glycerol, and lactate, and maximizing the glucose production
andsecretionrate.Afeasibleﬂuxdistributioninwhichglucose
is secreted was identiﬁed, with its secretion depending on the
uptake rate of the various uptake nutrients (Supplementary
Figure 3), demonstrating the ability of the model to perform
gluconeogenesis (KIDA et al, 1980; Chan et al, 2003).
One of the main functions that take place in the liver is the
conversion of ammonia to urea. Urea cycle deﬁciencies are
inborn errors of hepatic metabolism that may cause severe
hyperammonemia and hyperglutaminemia. In the study by
Lee et al (2000), metabolic ﬂuxes of urea secretion and
glutamine uptake were measured in vivo in subjects with urea
disorders, including argininosuccinate synthetase (ASS) deﬁ-
ciency, argininosuccinate lyase (ASL) deﬁciency, and or-
nithine transcarbamylase (OTC) deﬁciency, as well as in
controlhealthysubjects.As thesecretionandsynthesisofurea
are correlated with the consumption of dietary amino acids,
the ratio of urea secretion versus glutamine uptake can better
depict the functionality of the urea cycle than the rate of each
oftheﬂuxesbyitself,asdepictedin theresults obtained byLee
et al (2000). For each of the three disorders, we simulated the
metabolic phenotype of the healthy homozygote genotype
(enforcing a non-zero ﬂux through the corresponding reac-
tion), the mutated heterozygote genotype (limiting the ﬂux
through the corresponding reaction to 50% of its maximal rate
found by ﬂux variability analysis (FVA; Mahadevan and
Schilling, 2003), and the full knockout genotype (i.e.,
enforcing a zero ﬂux through the reaction), both in the generic
humanmodelandinthelivermodel. Speciﬁcally,ineachcase,
we computed the urea:glutamine ratio by sampling the space
of feasible ﬂux distributions, satisfying stoichiometric mass-
balance and reaction directionality constraints (Price et al,
2004), deriving a mean and s.d. of the ratio across 1000
sampled solutions. We ﬁnd that the results obtained by the
liver model better represent the experimentally observed
metabolic proﬁles than the generic model. Primarily, in the
liver model, the urea:glutamine ratio decreases monotonically
with the severity of the disease, with the exception of the full
knockout in the OTC simulation (Figure 3; Supplementary
Table I). In the liver model, the simulation of the healthy case
obtains a signiﬁcantly higher urea:glutamine ratio in compar-
ison to the ratio obtained in the full knockout of ASS and ASL
simulations (t-test P-values of 6 10
 2 and 1 10
 4, respec-
tively), unlike the generic model (t-test P-values of 0.8469 and
0.2235, respectively). In addition, the variance of the ratio
acrossthesolutionspacesthataredeﬁnedbythelivermodelis
fairly smaller than the variance of the one deﬁned by the
genericmodel(SupplementaryTableI).Theselatterresultsare
inlinewiththephenomenondescribedbyLeeetal(2000),that
the ratio is kept rather stable for each of the genotypes.
Cross-validation
To evaluate MBA’s performance in correctly identifying liver
reactions, it was applied to construct a liver model in a
standard ﬁve-fold cross-validation process. Speciﬁcally, MBA
was given various subsetsof the full core reactionsets,and the
reaction-content of the predicted MBA model was then
compared with the left-out core reactions data, that is, the
ability of MBA to correctly add the missing, left-out, liver
reactions was tested. The predictions of the algorithm are
signiﬁcantly enriched with the left-out test data (hypergeo-
metric P-value¼5.24 10
 15), obtaining accuracy of 0.5086,
recall of 0.5308, and precision of 0.2732. Another cross-
validationwasperformedina different manner,such thateach
timeoneofthemolecularomicsdatasetswasomittedfromthe
constructionstage.Furthermore,thepredictionsaresigniﬁcantly
enriched with the missing data set (mean hypergeometric
P-value¼4.33 10
 04), obtaining on average an accuracy
of 0.6174, recall of 0.7, and precision of 0.3844 (Figure 4).
Figure 3 The mean urea/glutamine ratio and the standard error in (A) the liver and (B) the generic model simulations of the healthy (i.e., normal homozygote), partial
(i.e., heterozygote) and full knockout cases.
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The liver model was applied to predict changes of ﬂux rates at
different hepatic metabolic conditions, and its prediction
accuracy was compared with that obtained by using the
original, generic human model. The predictions were tested
usingacomprehensivesetofﬂuxmeasurementsperformedby
Chan et al (2003). The experiments reported in the study by
Chan et al (2003) were performed in primary rat hepatocytes.
Hepatocytes form the main component of bioartiﬁcial liver
assist devices, which are destined to provide short-term
support to patients with acute liver failure (Busse et al, 1999;
Stockmann et al, 2000; Tzanakakis et al, 2000; Huiet al, 2001).
Hepatocytes were cultured in a standard hepatocyte culture
medium and were preconditioned with high or low levels of
insulin, and exposed to human plasmawith or without amino-
acid supplementation. Metabolic ﬂuxes were measured in
these four conditions.
Given this relatively rich liver ﬂux data, we set out to
perform a comprehensive comparison between four different
classiﬁers:(a)thelivermodel,(b)thegenericmodel,(c)aliver
model built using expression data only, and (d) a random
background model. The model built on tissue-speciﬁc expres-
sion data solely (model (c) is built and tested here too, since
such data are readily available for many tissues (while other
kinds of molecular data are yet more sporadic), and hence of
interest. The prediction test is conducted by providing the
models with the experimental ﬂux data of the exchange
reactions measured and predicting the resulting internal
ﬂuxes. To perform a rigorous comparison between the
classiﬁers, we track their performance using a standard
receiver–operator curve (ROC), which portrays the tradeoff
between the true positive (TPR) and false positiverates (FPRs)
of prediction as the decision threshold of a classiﬁer is varied.
Theoverallperformanceisthenprovidedbytheareaunderthe
curve (AUC), which varies between zero and one, the latter
denoting the performance of a perfect classiﬁer.
As evident from Figure 5, the liver model, obtaining an AUC
of 0.6745 and 0.6044 for predicting increasing and decreasing
ﬂuxes, respectively, markedly outperforms the generic model,
with predictions that obtain an AUC of 0.46073 and 0.5103 for
increasinganddecreasing ﬂuxes,respectively.Themodel built
based on liver-speciﬁc gene expression obtains an intermedi-
ate level of accuracy (an AUC of 0.57331 for increasing ﬂuxes
and 0.4806 for decreasing ones). Thus, even though it is
built based on a partial information core founded on gene
expression solely, it still outperforms the generic human
model. The ability of the different models to predict
extracellular ﬂuxes given the intracellular ﬂuxes, and in a
global ﬁve-fold cross-validation test (in which 4/5 of all
reactions are used to predict the remaining 1/5, irrespective of
their external/internal identity), is depicted in Supplementary
Figure 4. Overall, these results show that the liver model can
serve as a much better basis for predicting hepatic alterations
than the generic model, relying on just a fairly limited set of
ﬂux measurements.
Predicting metabolic biomarkers
Recently, Shlomi et al (2009) have shown that the generic
modelofDuarteetal(2007)canbeusedtosuccessfullypredict
changes in metabolite concentrations due to IEMs, represent-
ing diagnostic biomarkers that can be detected through
bioﬂuid metabolomics. As a further validation of the recon-
structed liver model, we repeated this analysis here focusing
on metabolic disorders that arise from mutations in hepatic
metabolic genes. The method is based on comparing the
concentrations of boundary metabolites in the disease
simulation versus the normal simulation. Each boundary
metabolite has anexchange reaction that transportsitfromthe
extracellular compartment to the intracellular compartment
andviceversa.Therefore,changesintheconcentrationofeach
of these metabolites can be inferred from comparing the ﬂux
intervals of its exchange reaction (representing uptake versus
secretion), by using FVA (see Materials and methods section;
Mahadevan and Schilling, 2003) in the simulated normal
versus disease states.
The initial set of metabolic disorders (documented in the
OMIM database) consists of 137 IEMs, the causative gene of
which is included in the generic human metabolic model
(Duarte et al, 2007), and are associated with one or more
known metabolic diagnostic biomarkers (Shlomi et al, 2009).
Figure 4 Prediction of missing core data via a ﬁve-fold cross-validation test. Each of the ﬁve columns represents the performance of the MBA algorithm in predicting
one omitted data source, using the four other data sources to construct the core for the algorithm.
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whosecausative gene is included in the reconstructed liver
model (Supplementary information, data set II). As evident
from Figure 6, the liver model improves upon the generic
model, with an AUC of 0.6691 for the liver model; versus an
AUC of 0.5868 achieved by the generic model (description of
the liver model’s biomarkers predictions is given in Supple-
mentary information, data set II). This time the model built
based solely on liver-speciﬁc gene expression performs
disappointingly, obtaining a lower level of accuracy than the
generic one, with an AUC of 0.5221. These results again show
the ability of the liver model to improve the identiﬁcation of
hepatic ﬂux alterations caused by dysfunctional enzymes
beyond the level yielded by the generic model, but also
highlight the importance of integrating multiple data sources
for the construction process if/when the latter are available.
Discussion
A rigorous, rapid computational method for the generation of
in silico tissue-speciﬁc metabolic models is presented. MBA
carves out a tissue-speciﬁc model out of a generic species
model, based on existing literature and molecular data
characterizing the tissue’s metabolism. The resulting model
satisﬁes stoichiometric, mass-balance and thermodynamic
constraints. The algorithm is structured according to the
accuracy level of the input data by the division of the tissue-
speciﬁc core into the more reliable human-curated (CH) and
the omics data (CM), which are treated with different levels of
conﬁdence. Despite the heuristic nature of the algorithm the
model construction is consistent, such that most reactions
selected for the ﬁnal model from the candidate solutions
appear in the large majority of the solutions. The algorithm is
applied to construct the ﬁrst stoichiometric genome-scale liver
metabolic model. The resulting liver model has the ability to
perform a range of hepatic metabolic functions, as well as
correctly depict the metabolic proﬁle of the liver at different
physiological and genetic conditions, in which it outperforms
the generic, human model.
The above approach is akin to a recently published method
by Christian et al (2009) in that it deﬁnes a set of reactions as a
core andattemptsto carveouttheminimalmodel that consists
of this core, but it differs in that it is based on optimization
rather than on a network expansion procedure that does not
consider the stochiometric constraints. MBA has its pros and
cons: on the pros side, it is a generic and fast approach to
generate tissue-speciﬁc models, which are fairly accurate and
useful. It is practically unlimited in its scalability, and can
process a large variety of data sources. Importantly, using
cross-validation, one can readily get a quantitative assessment
of the model consistency and reliability, and know where
things stand. On the cons side, several limitations should be
noted. First, the starting point—as the approach hinges upon a
generic species model, its accuracy depends on the quality of
thelatter.Thisdependencymaybealleviatedinthefuturewith
an extended computational approach that includes the
Figure 5 Prediction of experimental hepatic ﬂux data in primary hepatocytes exposed to plasma at low or high levels of insulin, with or without amino-acid
supplementation. The ROC curves (and the resulting AUCs) of all classiﬁers are presented separately for predicting (A) increasing and (B) decreasing internal ﬂuxes
(setting the exchange ﬂuxes to their experimentally measured values).
Figure 6 Prediction of metabolic biomarkers of IEMs. The ﬁgure depicts the
ROC curves (and the resulting AUCs) of the four classiﬁers, as in Figure 5.
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model construction. Second, the accuracy of different mole-
cular omics data that are used to determine the tissue core is
also an obvious limiting factor—to mitigate this effect our
approachtreatshuman-curatedpathwaysdatainapreferential
manner, and requires evidence from multiple molecular
sources, and yet, it is likely that not all inaccuracies in the
molecular data are ﬁltered out. Bearing these potential caveats
inmind, theaccuracyofthelivermodel generatedhereisquite
remarkable.
As the ﬁnal liver model consists of more than 95% of the CM
core (Table I), we further tested the added value of having a
moderate reliability core over simply including all of its
reactions in the resulting liver model (similarly to the high
reliability core CH). To this end, we constructed a model that
has a ﬁxed predetermined core composed of both the original
CH and CM reaction sets (i.e., now all deﬁned as CH reactions),
and studied its ability to predict ﬂux alterations. The resulting
modelisdenotedasastrictmodel,forits constructiondoesnot
tolerate a removal of any core reaction. The strict model’s
performance is rather similar to the performances of the liver
model in predicting inner ﬂuxes, obtaining an AUC of 0.6061
and 0.6433 for increasing and decreasing ﬂuxes. However,
comparison of the models by their ability to predict
extracellular ﬂuxes given the intracellular ﬂuxes, in a global
ﬁve-fold cross-validation test (Supplementary Figure 4), as well
as in biomarker prediction (Supplementary Figure 5), shows the
advantage of the liver model built by the standard, ﬂexible
MBA version. Although the liver model contains most of the
CM reactions, a considerable number of 100 reactions
differentiate between it and the strict model. This set of
reactions is involved in 22 metabolic pathways (see Supple-
mentary information, data set II, for full description), and
effects the performances of the models.
The MBA approach opens up opportunities for many
promising future applications. First and foremost, the liver
modeldevelopedinthisstudycanhelpintherationaldesignof
bioengineering artiﬁcial devices that emulate hepatic metabo-
lism (e.g., BAL; Yang et al, 2009). Hepatocytes, the main
components of the BAL (Strain and Neuberger, 2002), have a
tendency to rapidly lose their functionality due to metabolic
transformations (e.g., lipid accumulation and reduced ammo-
nia removal). Applying the liver metabolic model to optimize
the functionality of these cells and predict potential ways for
inhibiting the metabolic processes that contribute to this
unwanted transformation can assist in bypassing this hurdle.
Second, MBA can serve for the rapid development of an array
of metabolic models of a variety of human tissues, providing a
computational opportunity to probe the metabolism of such
tissues as the kidney, heart, and brain on a genomic scale.
Third, MBA can be used to generate tissue models for any
organism for which a generic model exists, such as Mus
musculus (Sheikh et al, 2005; Quek and Nielsen, 2008) and the
model plant Arabidopsis thaliana (Poolman et al, 2009).
Materials and methods
The model-building algorithm (MBA)
A metabolic network model, amenable to CBM, can be represented by
a four-tuple, (M, R, S, L), in which M denotes a set of metabolites, R
denotes a set of biochemical reactions, S 2 RjMjxjRj denotes reactions’
stoichiometry, and L 2 RjRj denotes constraints on reactions’ direc-
tionality (i.e., reﬂecting a lower bound on reactions’ ﬂux rate).
Reactions’ stoichiometry is represented by a stoichiometric matrix,
S, inwhich Si,j, represents the stoichiometric coefﬁcient of metabolite i
in reaction j.
A feasible ﬂux distribution within a metabolic network model, is
a vector v 2 RjRj, satisfying mass-balance (Sv¼0), and directionality
constraints (Lpv). A metabolic network model is considered
consistent if it enables to activate all of its reactions—that is, for each
reaction ri 2 R there exists a feasible ﬂux distribution v, such that
|vi|40.
Givenametabolicnetworkmodel,GM¼(MG,R G,S G,L G),referredto
as the generic model,apartial model,P M ¼(MP,R P,S P,L P), including
only a subset of the generic model’s reactions (RPCRG) can be deﬁned
on the basis of the corresponding subsets of metabolites, stoichio-
metry, and directionality constraints. Notably, a partial model of a
consistent generic model is not necessarily consistent by itself (i.e., it
may contain dead-end reactions that cannot be activated considering
all possible feasible ﬂux distributions).
Given a generic model, GM, and two sets of core reactions, CH and
CMCRG,knowntohaveahighandmoderateprobabilitytobeincludedin
some partial model, respectively, our goal is to derive the most
parsimonious, consistent, partial model PM, consisting of all reaction in
CH and a maximal number of reactions from CM.S p e c i ﬁ c a l l y ,w ew o u l d
like to identify PM by solving the following optimization problem:
Maximize |RP-CM|–e|RP/(CH,CM)|
s.t.
PM is consistent,
CHCRP
whereeisaparameterreﬂectingatradeoffbetweenobtainingthemost
parsimonious model (for a high value of e) and including a maximal
number of moderate probability reactions in the partial model (for a
low value of e). For the construction of the liver model e was set to 0.5.
To solve the above optimization problem, we use the following
simple search heuristic:
1. Deﬁne RP¼RG
2. Choose a random permutation, P, of reactions from the set
RG/(CH,CM)
3. For each reaction rAP
4. inactiveReactions¼CheckModelConsistency (RP, r)
5. eH¼inactiveReactions-CH
6. eM¼inactiveReactions-CM
7. eX¼inactiveReactions/(CH,CM)
8. If (|eH|¼0) AND (|eM|oe*|eX|) then RP¼RP/(eM,eX)
First, the current set of reactions in the partial model, RP, is initialized
to include all reactions in the generic model RG (1). Then, a random
permutationof all reactions that are neitherin the high-reliabilitycore,
CH, nor in the moderate-reliability core, CM (and hence their potential
removalfromthepartialmodelcanincreasetheoptimizationobjective
function) is generated. In (3), the potential removal of each reaction in
turn (based on the random order P) is evaluated. The procedure
CheckModelConsistency computes the set inactiveReactions that
consists of reactions in RP that cannot be activated due to the removal
of reaction r from RP. eH, eM, and eX are then computed to consist of
inactive reactions that belong to CH, CM or to none of the cores,
Table I Content of the input and output sets of MBA
Generic
model
CH Initial
CM
Liver model
Final CM Non core Total
Reactions 2469 779 304 291 757 1827
Metabolites 1587 873 484 457 922 1360
Genes 1479 898 346 338 250 1335
Pathways 83 37 39 38 37 80
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activate a high-reliability reaction, r would not be removed from RP
(3.b). Otherwise, if removal of r would increase the optimization
objective value, r will be removed from RP, along with the additional
reactions eM, eX that cannot be activated following its removal.
A naive implementation of CheckModelConsistency can simply
iterate through all reactions in RP applying FVA (Mahadevan and
Schilling,2003)tocheckwhethertheycancarrynon-zeroﬂuxwithina
feasible ﬂux distribution when r is removed. The naive algorithm is
computationally prohibitive, with an overall time complexity of
O(nkt), where n denotes the number of reactions in CH,CM,
k denotes the number of non-core reactions (|RP/CH,CL|), and
t denotes the (polynomial) complexity of each LP problem. Instead, a
simplespeed-uptechniquewasimplementedthataimstoconcurrently
activate multiple core reactions in the same LP problem, by trying to
maximize their total sum of ﬂux. These optimizations are repeated
severaltimesonamonotonicallydecreasingsetofcorereactions.Each
iteration is performed on a smaller subset of the core reactions, which
have received zero ﬂux in all previous iterations (see Supplementary
information, p 7 for pseudo-code and further explanation). These
speed-upsreducetherunningtimeby97%,incomparisontothenaive
approach. The total running time of the algorithm is B10–20min
depending on the cores’ size.
As the resulting model depends on the chosen reaction scanning
order,the algorithmisexecutedrepeatedlyfora numberoftimes(1000
in the results presented here) with different, random scanning orders.
Each run results in a candidate model. All 1000 candidate models are
then processed to assign the CM and non-core reactions with scores,
representing the fraction of candidate models in which they appear.
An aggregative modelis built byconsideringthe scores acrossall runs,
starting with the CH and incrementally adding reactions according to
their conﬁdence score until a consistent, viable model is obtained.
Model availability
The liver model, in excel and SBML format, is available as
Supplementary information. MBA can be applied via a web server at
http://imat.cs.tau.ac.il.
Predicting ﬂux measurements
The liver model was applied to predict changes in metabolic ﬂux rates
underdifferenthepaticconditions.The predictions were compared with a
set of ﬂux measurements, including 23 exchange ﬂuxes (uptake of
metabolites)and22 innerﬂuxes(Chan etal, 2003; a completedescription
of the experimental ﬂux data is given in Supplementary information, data
set II). The measurements were obtained from primary rat hepatocytes in
four metabolic conditions: high/low-insulin preconditioning with (HPA/
LPA) or without (HP/LP) amino-acid supplementations.
Quadratic programming (QP) was appliedto ﬁrst ﬁnd a feasible ﬂux
distribution, satisfying stoichiometric mass-balance and reaction
directionality constraints, that is as close as possible to the measured
ﬂux through exchange reactions. This process was executed both for
the generic and the liver models in each of the four growth conditions.
To explore the metabolic proﬁle that is deduced by this optimal match
with the measured exchange ﬂuxes, FVA (Mahadevan and Schilling,
2003) was used to predict a range of possible ﬂuxes through all
reactions in the model, while ﬁxing the ﬂux through the measured
exchange reactions to the values computed using QP (the maximal
uptake rate of other exchange reactions in the model was set to 10% of
glutamine uptake rate (Chan et al, 2003).
Changes in metabolic ﬂux were predicted in comparison with the
reference condition HP. For each reaction, we compute the difference
betweenitsintervalintheHPconditiontoitsintervalintheotherthree
conditions, that is, change(vi)¼(max(vi)-ref_max(vi))þ(min(vi)-ref_
min(vi)). A reaction is predicted to increase or decrease under the
conditions for which either (1) or (2) listed below holds, respectively,
where f is a threshold value. Otherwise, it is considered to be
unchanged (Supplementary Figure 6). In addition, the change in the
interval is normalized by its size (3), to account the signiﬁcance of the
ﬂux alteration. The ROC curves of the predictions were plotted with
increasing thresholds values (Bock et al, 1991).
1. change(vi)/Mi4f
2. change(vi)/Mio f
3. Mi¼|mean(min(vi), max(vi), min(ref_vi), max(ref_vi))|
Biomarkers prediction
WeappliedthecomputationalmethoddescribedbyShlomietal(2009)
to systematically predict metabolic biomarkers characterizing 84
hepatic metabolic disorders (documented in the OMIM database),
thatis,disorderscausativegeneofwhichis included inthe liver model
(Supplementary information, data set II). The method relies on
comparing the concentrations of boundary metabolites in the disease
simulation versus the normal simulation. A boundary metabolite is
deﬁned as a metabolite that can be transported from the extracellular
compartmenttotheintracellularcompartment,andviceversa,through
an exchange reaction. Changes in the concentration of a boundary
metabolite can be inferred from shifts in the interval of the minimum/
maximum ﬂux values of its exchange reaction. For each metabolic
reaction r, we computed the interval of exchange reactions e, via FVA,
when r is forced to be either active or inactive, simulating the normal
and disease case, respectively. If m is a boundary metabolite with an
exchange reaction interval of A¼(mina,maxa) in the normal simula-
tion and B¼(minb,maxb) in the disease simulation, then m is a
biomarker if either of the following holds:
(1) AoB
(2) BoA
In adddition, based on the deﬁnition of Shlomi et al (2009), we deﬁne:
AoBifððmina þ Mominb andmaxapmaxbÞorðminapminb andmaxa
þ MomaxbÞÞM ¼ f jmeanðminðviÞ;maxðviÞ;minðref viÞ;maxðref viÞÞj
where f is the decision threshold value according to which we plot the
ROC curve.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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